BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/22/2026 6:58:05 AM | Browse: 5 | Download: 0
Publication Name World Journal of Gastroenterology
Manuscript ID 118763
Country China
Category Gastroenterology & Hepatology
Manuscript Type Opinion Review
Article Title Prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer: Current evidence, persistent uncertainties, and future perspectives
Manuscript Source Invited Manuscript
All Author List Ze-Wei Cheng, Yi-Ze Liang, Meng Wei, Zhi-Bo Yan, Guo-Rui Sun, Xiao-Han Cui and Wen-Bin Yu
Funding Agency and Grant Number
Funding Agency Grant Number
Horizontal Project of Shandong University No. 6010123193, No. 6010121066, and No. 6010125120
Corresponding Author Wen-Bin Yu, MD, PhD, Professor, Department of General Surgery, Qilu Hospital of Shandong University, No. 107 Wenhuaxi Road, Jinan 250012, Shandong Province, China. wenbin_yu2003@163.com
Key Words Gastric cancer; Prophylactic hyperthermic intraperitoneal chemotherapy; Peritoneal recurrence; Patient selection; Safety; Prognosis
Core Tip Prophylactic hyperthermic intraperitoneal chemotherapy aims to eliminate occult free cancer cells following curative gastrectomy for locally advanced gastric cancer, thereby reducing peritoneal recurrence. While meta-analyses suggest potential improvements in survival and peritoneal control, conflicting trial results and persistent protocol heterogeneity preclude definitive recommendations. Although prophylactic hyperthermic intraperitoneal chemotherapy appears generally safe, it carries distinct risks that demand vigilant monitoring, including renal impairment, pulmonary dysfunction, and hematologic toxicity. Optimal patient selection, guided by serosal invasion, nodal burden, diffuse histology, and positive peritoneal cytology, remains paramount. Ongoing trials and novel combinatorial strategies may help clarify its therapeutic role.
Citation Cheng ZW, Liang YZ, Wei M, Yan ZB, Sun GR, Cui XH, Yu WB. Prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer: Current evidence, persistent uncertainties, and future perspectives. World J Gastroenterol 2026; In press
Received
2026-01-12 01:37
Peer-Review Started
2026-01-12 01:37
First Decision by Editorial Office Director
2026-02-04 10:02
Return for Revision
2026-02-04 10:02
Revised
2026-02-13 15:20
Publication Fee Transferred
Second Decision by Editor
2026-04-22 02:36
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-04-22 06:58
Articles in Press
2026-04-22 06:58
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com